Bayer HealthCare and Onyx Pharmaceuticals, Inc. has announced that a planned review by an independent data monitoring committee (DMC) found that Nexavar (sorafenib) tablets significantly improved overall survival, progression free survival and time to progression in an Asia-Pacific regional phase III trial of patients with advanced hepatocellular carcinoma (HCC), the most common form of liver cancer.
Based on the DMC's recommendation, the trial will be stopped to allow all patients to receive treatment with Nexavar. Data from this study will be submitted for presentation at an upcoming scientific meeting.
The Asia-Pacific liver cancer study was conducted at the request of Asian health authorities in order to provide supplemental information on Nexavar's efficacy and safety in Asian-Pacific patient populations. Bayer has completed supplemental regulatory filings in several countries/regions including Europe, China, and the US for Nexavar in the treatment of liver cancer. These filings were based on positive data from the pivotal phase III SHARP study announced earlier this year. Additional regulatory submissions for Nexavar in liver cancer are being finalized.
"Liver cancer incidence continues to rise in the Asia-Pacific region, due to the high prevalence of hepatitis B virus infections," said Dr Ann-Lii Cheng, principal investigator and Professor of Medicine, National Taiwan University Hospital. "These study results confirm that Nexavar's efficacy and tolerability in liver cancer extends across ethnic groups and geographies and suggest that Nexavar could meet a tremendous unmet need for patients and families impacted by this devastating disease."
Hepatocellular carcinoma (HCC) is the most common form of liver cancer and is responsible for about 90 per cent of the primary malignant liver tumours in adults. It is the sixth most common cancer in the world and the third leading cause of cancer-related deaths globally. Over 600,000 new cases of HCC are diagnosed globally each year. In 2002, approximately 600,000 people died of HCC, including approximately 360,000 in China, Korea and Japan, 13,000 in the United States and 57,000 in Europe. Risk factors for liver cancer include ongoing (chronic) infection with the hepatitis B virus (HBV) and/or hepatitis C virus (HCV).
Nexavar is currently approved in more than 50 countries, including the United States and those in the European Union, for the treatment of patients with advanced kidney cancer. In Europe, Nexavar is approved for the treatment of patients with advanced renal cell carcinoma (RCC) who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy. Nexavar is also being evaluated by the companies, international study groups, government agencies, and individual investigators as a single agent or combination treatment in a wide range of other cancers, including adjuvant therapy for kidney cancers, metastatic melanoma, breast cancer and non-small cell lung cancer (NSCLC).